Head-to-head · Cost-Efficiency Index
Found vs Thryve
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Found
Insured shoppers willing to prepay 12 months upfront to reach the lowest advertised rate, who also want behavior-change coaching bundled in.
Visit FoundThryve
Not currently recommendable — include only for completeness while the underlying site remains this undocumented.
Visit ThryveThe verdict
Found takes it, leading the Cost-Efficiency Index 88 to 22. A real insurance-billing pathway on both molecules — but the widely-quoted $99/mo headline requires an insurance plan AND a full year prepaid upfront; the true no-commitment rate is $199-289/mo. Thryve still earns a C — Not currently recommendable — include only for completeness while the underlying site remains this undocumented.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Found.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Found | Thryve |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 22/100 |
| Semaglutide / mo | $199/mo (insurance-linked) | $99/mo (drug not specified — site never names semaglutide or tirzepatide) |
| Tirzepatide / mo | $199/mo (insurance-linked) | $99/mo (drug not specified — site never names semaglutide or tirzepatide) |
| Semaglutide / yr (modeled) | $2,388 | $1,188 |
| Tirzepatide / yr (modeled) | $2,388 | $1,188 |
| Coverage | All 50 states | Not disclosed |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #7 | #501 |
Found
88/100Where the value is
- Genuine insurance-billing pathway, unlike most cash-only compounded competitors — most members reportedly pay under $30/visit
- Nationwide
- Strong behavior-change program adds value
The tradeoffs
- The advertised '$99/mo' headline requires BOTH an insurance-linked plan AND a 12-month prepay at once — the real month-to-month rate is $199/mo (insured) or $289/mo (cash-pay), 2-3x the headline
- Coaching subscription can't be unbundled, which reduces contract flexibility
Thryve
22/100Where the value is
- A low headline price is advertised, if a reader wants to investigate directly
The tradeoffs
- Never names which drug is being sold — no mention of semaglutide, tirzepatide, or any other active ingredient anywhere on the site
- No dose, no state-coverage list, no named clinician, and no named pharmacy found anywhere
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.